Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women

Manubai Nagamani, Alexandria Szymajda, Vicken Sepilian, Randall Urban, Charles Gilkison

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To investigate the effect of raloxifene on insulin sensitivity, β-cell function, hepatic insulin clearance, and glucose tolerance in postmenopausal women. Design: Prospective study. Setting: University of Texas Medical Branch at Galveston, Texas. Patient(s): Twenty normal postmenopausal women. Intervention(s): An oral glucose tolerance test (OGTT) was performed on all study participants before and after treatment with 60 mg of raloxifene daily for 3 months. Blood samples were obtained at baseline and 1, 2, and 3 hours after 75-g oral glucose administration for measurement of glucose, insulin, proinsulin, and c-peptide levels. Insulin tolerance test (ITT) and euglycemic clamp studies were also performed before and after treatment. Main Outcome Measure(s): Glucose and insulin area under curve (AUC) were calculated. The c-peptide to insulin ratio was determined to assess hepatic clearance of insulin. The homeostasis model assessment (HOMA) was used to calculate the index of insulin resistance (HOMA-IR) and β-cell function (HOMA-%β). Insulin sensitivity was assessed by insulin tolerance test and glucose infusion rate (GIR) during euglycemic clamp studies. Result(s): There was no change in fasting or AUC glucose levels. Fasting insulin levels were not statistically significantly different, but the insulin levels at 2 hours and insulin AUC were higher after treatment compared with before treatment. Proinsulin, c-peptide levels, and HOMA-%β did not change. The c-peptide to insulin molar ratio was statistically significantly decreased after treatment. There was no change in insulin sensitivity. Conclusion(s): These results indicate that raloxifene has no adverse effect on insulin sensitivity or glucose tolerance, and it does not affect β-cell function. After glucose load, raloxifene decreases hepatic insulin extraction and thus conserves insulin, which may be beneficial to patients with decreased β-cell reserve or those predisposed to type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)614-619
Number of pages6
JournalFertility and Sterility
Volume89
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Insulin Resistance
Hepatocytes
Insulin
Glucose
Homeostasis
Area Under Curve
Proinsulin
Peptides
Glucose Clamp Technique
Glucose Tolerance Test
Raloxifene Hydrochloride
Fasting
Therapeutics
Liver
Type 2 Diabetes Mellitus
Oral Administration
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • β-cell function
  • insulin sensitivity
  • Raloxifene

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women. / Nagamani, Manubai; Szymajda, Alexandria; Sepilian, Vicken; Urban, Randall; Gilkison, Charles.

In: Fertility and Sterility, Vol. 89, No. 3, 03.2008, p. 614-619.

Research output: Contribution to journalArticle

Nagamani, Manubai ; Szymajda, Alexandria ; Sepilian, Vicken ; Urban, Randall ; Gilkison, Charles. / Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women. In: Fertility and Sterility. 2008 ; Vol. 89, No. 3. pp. 614-619.
@article{1ec5147c5b92410aa688678f7dafbc6c,
title = "Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women",
abstract = "Objective: To investigate the effect of raloxifene on insulin sensitivity, β-cell function, hepatic insulin clearance, and glucose tolerance in postmenopausal women. Design: Prospective study. Setting: University of Texas Medical Branch at Galveston, Texas. Patient(s): Twenty normal postmenopausal women. Intervention(s): An oral glucose tolerance test (OGTT) was performed on all study participants before and after treatment with 60 mg of raloxifene daily for 3 months. Blood samples were obtained at baseline and 1, 2, and 3 hours after 75-g oral glucose administration for measurement of glucose, insulin, proinsulin, and c-peptide levels. Insulin tolerance test (ITT) and euglycemic clamp studies were also performed before and after treatment. Main Outcome Measure(s): Glucose and insulin area under curve (AUC) were calculated. The c-peptide to insulin ratio was determined to assess hepatic clearance of insulin. The homeostasis model assessment (HOMA) was used to calculate the index of insulin resistance (HOMA-IR) and β-cell function (HOMA-{\%}β). Insulin sensitivity was assessed by insulin tolerance test and glucose infusion rate (GIR) during euglycemic clamp studies. Result(s): There was no change in fasting or AUC glucose levels. Fasting insulin levels were not statistically significantly different, but the insulin levels at 2 hours and insulin AUC were higher after treatment compared with before treatment. Proinsulin, c-peptide levels, and HOMA-{\%}β did not change. The c-peptide to insulin molar ratio was statistically significantly decreased after treatment. There was no change in insulin sensitivity. Conclusion(s): These results indicate that raloxifene has no adverse effect on insulin sensitivity or glucose tolerance, and it does not affect β-cell function. After glucose load, raloxifene decreases hepatic insulin extraction and thus conserves insulin, which may be beneficial to patients with decreased β-cell reserve or those predisposed to type 2 diabetes.",
keywords = "β-cell function, insulin sensitivity, Raloxifene",
author = "Manubai Nagamani and Alexandria Szymajda and Vicken Sepilian and Randall Urban and Charles Gilkison",
year = "2008",
month = "3",
doi = "10.1016/j.fertnstert.2007.03.083",
language = "English (US)",
volume = "89",
pages = "614--619",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women

AU - Nagamani, Manubai

AU - Szymajda, Alexandria

AU - Sepilian, Vicken

AU - Urban, Randall

AU - Gilkison, Charles

PY - 2008/3

Y1 - 2008/3

N2 - Objective: To investigate the effect of raloxifene on insulin sensitivity, β-cell function, hepatic insulin clearance, and glucose tolerance in postmenopausal women. Design: Prospective study. Setting: University of Texas Medical Branch at Galveston, Texas. Patient(s): Twenty normal postmenopausal women. Intervention(s): An oral glucose tolerance test (OGTT) was performed on all study participants before and after treatment with 60 mg of raloxifene daily for 3 months. Blood samples were obtained at baseline and 1, 2, and 3 hours after 75-g oral glucose administration for measurement of glucose, insulin, proinsulin, and c-peptide levels. Insulin tolerance test (ITT) and euglycemic clamp studies were also performed before and after treatment. Main Outcome Measure(s): Glucose and insulin area under curve (AUC) were calculated. The c-peptide to insulin ratio was determined to assess hepatic clearance of insulin. The homeostasis model assessment (HOMA) was used to calculate the index of insulin resistance (HOMA-IR) and β-cell function (HOMA-%β). Insulin sensitivity was assessed by insulin tolerance test and glucose infusion rate (GIR) during euglycemic clamp studies. Result(s): There was no change in fasting or AUC glucose levels. Fasting insulin levels were not statistically significantly different, but the insulin levels at 2 hours and insulin AUC were higher after treatment compared with before treatment. Proinsulin, c-peptide levels, and HOMA-%β did not change. The c-peptide to insulin molar ratio was statistically significantly decreased after treatment. There was no change in insulin sensitivity. Conclusion(s): These results indicate that raloxifene has no adverse effect on insulin sensitivity or glucose tolerance, and it does not affect β-cell function. After glucose load, raloxifene decreases hepatic insulin extraction and thus conserves insulin, which may be beneficial to patients with decreased β-cell reserve or those predisposed to type 2 diabetes.

AB - Objective: To investigate the effect of raloxifene on insulin sensitivity, β-cell function, hepatic insulin clearance, and glucose tolerance in postmenopausal women. Design: Prospective study. Setting: University of Texas Medical Branch at Galveston, Texas. Patient(s): Twenty normal postmenopausal women. Intervention(s): An oral glucose tolerance test (OGTT) was performed on all study participants before and after treatment with 60 mg of raloxifene daily for 3 months. Blood samples were obtained at baseline and 1, 2, and 3 hours after 75-g oral glucose administration for measurement of glucose, insulin, proinsulin, and c-peptide levels. Insulin tolerance test (ITT) and euglycemic clamp studies were also performed before and after treatment. Main Outcome Measure(s): Glucose and insulin area under curve (AUC) were calculated. The c-peptide to insulin ratio was determined to assess hepatic clearance of insulin. The homeostasis model assessment (HOMA) was used to calculate the index of insulin resistance (HOMA-IR) and β-cell function (HOMA-%β). Insulin sensitivity was assessed by insulin tolerance test and glucose infusion rate (GIR) during euglycemic clamp studies. Result(s): There was no change in fasting or AUC glucose levels. Fasting insulin levels were not statistically significantly different, but the insulin levels at 2 hours and insulin AUC were higher after treatment compared with before treatment. Proinsulin, c-peptide levels, and HOMA-%β did not change. The c-peptide to insulin molar ratio was statistically significantly decreased after treatment. There was no change in insulin sensitivity. Conclusion(s): These results indicate that raloxifene has no adverse effect on insulin sensitivity or glucose tolerance, and it does not affect β-cell function. After glucose load, raloxifene decreases hepatic insulin extraction and thus conserves insulin, which may be beneficial to patients with decreased β-cell reserve or those predisposed to type 2 diabetes.

KW - β-cell function

KW - insulin sensitivity

KW - Raloxifene

UR - http://www.scopus.com/inward/record.url?scp=40249093057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40249093057&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2007.03.083

DO - 10.1016/j.fertnstert.2007.03.083

M3 - Article

VL - 89

SP - 614

EP - 619

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 3

ER -